Hexagon Bio Overview

  • Year Founded
  • 2016

Year Founded

  • Status
  • Private

  • Employees
  • 76

Employees

  • Latest Deal Type
  • Series C

  • Latest Deal Amount
  • $62M

  • Investors
  • 14

Hexagon Bio General Information

Description

Developer of antibody-drug conjugate payloads designed to support targeted cancer treatment. The company's research focuses on drug payloads with alternative mechanisms of action beyond topoisomerase and tubulin inhibition, enabling oncology drug developers to explore targeted therapies and address resistance associated with existing antibody-drug conjugate payloads.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 1490 O'Brien Drive
  • Suite E
  • Menlo Park, CA 94025
  • United States
+1 (650)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • 1490 O'Brien Drive
  • Suite E
  • Menlo Park, CA 94025
  • United States
+1 (650)

Hexagon Bio Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Hexagon Bio Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Later Stage VC (Series C) 23-Oct-2026 $62M Completed Clinical Trials - Phase 1
4. Later Stage VC (Series B) 13-Feb-2023 Completed Clinical Trials - Phase 1
3. Later Stage VC (Series B) 22-Sep-2021 Completed Clinical Trials - Phase 1
2. Early Stage VC (Series A) 15-Sep-2020 $47M $55.3M Completed Startup
1. Seed Round 18-Jul-2017 $8.3M $8.3M Completed Startup
To view Hexagon Bio’s complete valuation and funding history, request access »

Hexagon Bio Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series C2
Series C1
Series C
Series B
Series A2
Series A1
Series A Prime 15,421,955 $0.000100 8% $3.96 $3.96 1x $3.96 7.07%
Seed 3,256,567 $0.000100 8% $2.58 $2.58 1x $2.58 1.49%
To view Hexagon Bio’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Hexagon Bio Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of antibody-drug conjugate payloads designed to support targeted cancer treatment. The company's research focu
Drug Discovery
Menlo Park, CA
76 As of 2026

Cambridge, MA
 

Niel, Belgium
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Hexagon Bio Competitors (96)

One of Hexagon Bio’s 96 competitors is Exo Therapeutics, a Venture Capital-Backed company based in Cambridge, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Exo Therapeutics Venture Capital-Backed Cambridge, MA
etherna Formerly VC-backed Niel, Belgium
Arvinas Formerly VC-backed New Haven, CT
CytomX Therapeutics Formerly VC-backed South San Francisco, CA
Agomab Therapeutics Formerly VC-backed Antwerp, Belgium
You’re viewing 5 of 96 competitors. Get the full list »

Hexagon Bio Patents

Hexagon Bio Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026227038-A2 Eif4a modulators and uses thereof Pending 25-Apr-2025
WO-2026227043-A1 Substituted beta alanine conjugates and uses thereof Pending 25-Apr-2025
WO-2025226868-A1 Antibody drug conjugates and uses thereof Pending 23-Apr-2024
EP-4805503-A1 Methods for identification of compound interaction partners and compounds produced by gene clusters Pending 08-Nov-2023
WO-2025101762-A1 Methods for identification of compound interaction partners and compounds produced by gene clusters Inactive 08-Nov-2023 C12N15/80
To view Hexagon Bio’s complete patent history, request access »

Hexagon Bio Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Hexagon Bio Investors (14)

Investor Name Investor Type Holding Investor Since Participating Rounds
bpd partners Family Office Minority
CPP Investments Asset Manager Minority
Casdin Capital Venture Capital Minority
Nextech Invest Venture Capital Minority
SoftBank Investment Advisers Growth/Expansion Minority
You’re viewing 5 of 14 investors. Get the full list »

Hexagon Bio Investments (1)

Hexagon Bio’s most recent deal was a Joint Venture with Developer of New Crop Protection Solutions (Corteva / Hexagon Bio). The deal was made on 22-Dec-2025.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Developer of New Crop Protection Solutions (Corteva / Hexagon Bio) 22-Dec-2025 Joint Venture Agricultural Chemicals
To view Hexagon Bio’s complete investments history, request access »

Hexagon Bio FAQs

  • When was Hexagon Bio founded?

    Hexagon Bio was founded in 2016.

  • Where is Hexagon Bio headquartered?

    Hexagon Bio is headquartered in Menlo Park, CA.

  • What is the size of Hexagon Bio?

    Hexagon Bio has 76 total employees.

  • What industry is Hexagon Bio in?

    Hexagon Bio’s primary industry is Drug Discovery.

  • Is Hexagon Bio a private or public company?

    Hexagon Bio is a Private company.

  • What is the current valuation of Hexagon Bio?

    The current valuation of Hexagon Bio is .

  • What is Hexagon Bio’s current revenue?

    The current revenue for Hexagon Bio is .

  • How much funding has Hexagon Bio raised over time?

    Hexagon Bio has raised $256M.

  • Who are Hexagon Bio’s investors?

    bpd partners, CPP Investments, Casdin Capital, Nextech Invest, and SoftBank Investment Advisers are 5 of 14 investors who have invested in Hexagon Bio.

  • Who are Hexagon Bio’s competitors?

    Exo Therapeutics, etherna, Arvinas, CytomX Therapeutics, and Agomab Therapeutics are some of the 96 competitors of Hexagon Bio.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process